Artiva Biotherapeutics Inc
ARTV3.040USD
+0.210+7.42%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
74.06MCap. mercado
PérdidaP/E TTM
Más Datos de Artiva Biotherapeutics Inc Compañía
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Información de la empresa
Símbolo de cotizaciónARTV
Nombre de la empresaArtiva Biotherapeutics Inc
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoDr. Fred Aslan, M.D.
Número de empleados89
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 19
Dirección5505 Morehouse Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92121
Teléfono18582674467
Sitio Webhttps://www.artivabio.com/
Símbolo de cotizaciónARTV
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoDr. Fred Aslan, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 19 de jul
Actualizado: sáb., 19 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
58.50%
Corporation
18.75%
Investment Advisor
13.06%
Investment Advisor/Hedge Fund
6.64%
Private Equity
4.92%
Hedge Fund
2.37%
Individual Investor
1.24%
Research Firm
0.43%
Sovereign Wealth Fund
0.12%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
102
25.86M
106.14%
+3.25M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Capital World Investors
866.62K
3.56%
-48.76K
-5.33%
Mar 31, 2025
The Vanguard Group, Inc.
858.21K
3.52%
-8.71K
-1.00%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
410.46K
1.68%
+94.70K
+29.99%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Biotechnology ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
Ver más
iShares Biotechnology ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
